Contact
15 Apr 20
News
15 Apr 20

Biocomposites Appoints President, Biocomposites Inc.

Targeting reconstruction, spine, trauma and foot and ankle

Keele, UK, 15 April 2020 – Biocomposites, an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the appointment of Will Connelly as President, Biocomposites Inc., covering the Americas – effective 20 April 2020. His role will focus on growing Biocomposites Inc. throughout the Americas in reconstruction, spine, trauma and foot and ankle.

Michael Harris, Chief Executive Officer of Biocomposites, said: “I am delighted to welcome Will to the team. His track record of success in orthopaedics, trauma and spine will serve us well as we continue to focus on growing our business to meet the needs of surgeons managing infection in bone and soft tissue. The recent launch of a STIMULAN 3cc pack size in the U.S. and securing a new contract with HealthTrust covering 25% of our target market, gives us a strong foundation to exploit opportunities as the market returns.”

Will Connelly, commented: “I am extremely pleased to be joining the team at Biocomposites to build on its success in the U.S., Canada, Mexico and South America. Over the years I’ve seen first-hand the value surgeons place on the STIMULAN platform, and with approvals to mix it with antibiotics in Canada and Mexico, I’m excited to get started.”

Will brings demonstrated analytical, strategic and business development capabilities with highly relevant experience. He joins Biocomposites from Aesculap Implant Systems where he was Executive Team Member and Vice President, Sales, Orthopaedics and Spine. Prior to Aesculap, he held the positions of Regional Vice President for reconstruction and trauma with Smith and Nephew and Director of US Sales with Orthofix.

Contact for Media enquiries

Optimum Strategic Communications

Mary Clark, Stephen Adams, Katie Flint, Nellie Stephens
Tel: +44 (0)20 3922 1906
biocomposites@optimumcomms.com

About Biocomposites

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, South America, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds and bone cements for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry and sports injuries. Biocomposites’ products are now used in over 1 million procedures per annum and sold in more than 100 countries around the world. In January 2026 Biocomposites was named as one of the UK’s 100 fastest growing technology companies by The Sunday Times. See here for The Sunday Times’ 100 Tech 2026 list. Please visit biocomposites.com to learn more.

About SYNICEMTM bone cements

SYNICEMTM bone cements have been developed to provide the ideal interface between prosthesis and bone – optimised to provide secure and stable fixation for joint replacement surgery, including between irregular bone surfaces and the prosthesis. SYNICEMTM bone cements are manufactured in-house under strictly controlled conditions using out proprietary process. The SYNICEMTM bone cement range includes cements loaded with gentamicin (an antibiotic) for revision procedures in patients at high risk of infection due to gentamicin-sensitive bacteria and patients with compromised immunity. SYNICEMTM bone cements are already used in more than 100 countries around the world.

Other news

Listed below is a list of the 4 most recent news updates made by Biocomposties


Visit our News & Events page

Library

Interested in other types of our content? See a list of some of our most recent below.

Explore Library